tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksFDA CalendarMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

Denali Therapeutics 9.143M share Spot Secondary priced at $17.50
The FlyDenali Therapeutics 9.143M share Spot Secondary priced at $17.50
3h ago
DNLI
Closing Bell Movers: GE Vernova up 6% on raised outlook, doubled dividend
PremiumThe Fly
Closing Bell Movers: GE Vernova up 6% on raised outlook, doubled dividend
14h ago
GEV
GME
Denali Therapeutics TBA Spot Secondary; price range $17.00-$18.00
PremiumThe Fly
Denali Therapeutics TBA Spot Secondary; price range $17.00-$18.00
17h ago
DNLI
Denali Therapeutics offers to sell $200M in common stock
PremiumThe Fly
Denali Therapeutics offers to sell $200M in common stock
17h ago
DNLI
Denali Therapeutics price target raised to $29 from $26 at BofA
PremiumThe Fly
Denali Therapeutics price target raised to $29 from $26 at BofA
5d ago
DNLI
Denali Therapeutics price target raised to $31 from $30 at Wedbush
PremiumThe FlyDenali Therapeutics price target raised to $31 from $30 at Wedbush
5d ago
DNLI
Denali Therapeutics: Promising Pipeline and Strategic Advancements Justify Buy Rating
Premium
Ratings
Denali Therapeutics: Promising Pipeline and Strategic Advancements Justify Buy Rating
5d ago
DNLI
Denali Therapeutics: Promising Future with Strategic Agreements and Innovative Programs
Premium
Ratings
Denali Therapeutics: Promising Future with Strategic Agreements and Innovative Programs
6d ago
DNLI
Denali Therapeutics Secures $275M Royalty Funding Deal
PremiumCompany Announcements
Denali Therapeutics Secures $275M Royalty Funding Deal
6d ago
8K
DNLI
Denali Therapeutics Hosts Investor Day, Updates Pipeline
PremiumCompany Announcements
Denali Therapeutics Hosts Investor Day, Updates Pipeline
6d ago
8K
DNLI
Royalty Pharma, Denali Therapeutics enter $275M royalty funding agreement
PremiumThe Fly
Royalty Pharma, Denali Therapeutics enter $275M royalty funding agreement
6d ago
DNLI
RPRX
Denali Therapeutics, Royalty Pharma announce $275M royalty funding agreement
PremiumThe Fly
Denali Therapeutics, Royalty Pharma announce $275M royalty funding agreement
6d ago
DNLI
RPRX
Denali Therapeutics price target lowered to $26 from $27 at BofA
PremiumThe FlyDenali Therapeutics price target lowered to $26 from $27 at BofA
23d ago
DNLI
Denali Therapeutics price target lowered to $26 from $27 at BofA
Premium
The Fly
Denali Therapeutics price target lowered to $26 from $27 at BofA
24d ago
DNLI
Denali Therapeutics: Promising Future with Tivi Approval and Unique Brain Shuttling Platform
Premium
Ratings
Denali Therapeutics: Promising Future with Tivi Approval and Unique Brain Shuttling Platform
1M ago
DNLI
Denali Therapeutics: Strategic Positioning and Growth Potential with Pioneering TfR-Enabled Medicine Launch
PremiumRatings
Denali Therapeutics: Strategic Positioning and Growth Potential with Pioneering TfR-Enabled Medicine Launch
1M ago
DNLI
Denali Therapeutics Reports Increased Losses Amid Strategic Collaborations
PremiumCompany Announcements
Denali Therapeutics Reports Increased Losses Amid Strategic Collaborations
1M ago
DNLI
Denali Therapeutics: Promising Pipeline and Strategic Progress Justify Buy Rating
PremiumRatings
Denali Therapeutics: Promising Pipeline and Strategic Progress Justify Buy Rating
1M ago
DNLI
Denali Therapeutics reports Q3 EPS (74c), consensus (76c)
PremiumThe Fly
Denali Therapeutics reports Q3 EPS (74c), consensus (76c)
1M ago
DNLI
Denali says chief medical officer Carole Ho to depart to join Eli Lilly
PremiumThe FlyDenali says chief medical officer Carole Ho to depart to join Eli Lilly
1M ago
LLY
ARGX
Denali Therapeutics: Buy Rating Affirmed Amid Temporary FDA Delay and Promising Pipeline
Premium
Ratings
Denali Therapeutics: Buy Rating Affirmed Amid Temporary FDA Delay and Promising Pipeline
2M ago
DNLI
Denali Therapeutics Faces FDA Review Extension
Premium
Company Announcements
Denali Therapeutics Faces FDA Review Extension
2M ago
8K
DNLI

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >